longbridge

PHVS

31.5400.41%

PHVS: Oral deucrictibant shows high efficacy and safety for HAE, with launch targeted for April 2024

Quartr
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Deucrictibant, an oral therapy for hereditary angioedema, demonstrated strong efficacy and safety in phase III trials, with regulatory reviews progressing in the US and Europe. Commercial launch preparations are on track for 2024, and the pipeline is expanding to address broader bradykinin-mediated disorders.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Deucrictibant, an oral therapy for hereditary angioedema, demonstrated strong efficacy and safety in phase III trials, with regulatory reviews progressing in the US and Europe. Commercial launch preparations are on track for 2024, and the pipeline is expanding to address broader bradykinin-mediated disorders.

Based on

Disclaimer
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Source: Quartr The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy